Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel cytokine-driven hyper-inflammation, thrombotic microangiopathy and NET-driven immunothrombosis, thereby leading to multi-organ failure. Complement therapeut...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Immunol
Hlavní autoři: Mastellos, Dimitrios C., Pires da Silva, Bruno G.P., Fonseca, Benedito A.L., Fonseca, Natasha P., Auxiliadora-Martins, Maria, Mastaglio, Sara, Ruggeri, Annalisa, Sironi, Marina, Radermacher, Peter, Chrysanthopoulou, Akrivi, Skendros, Panagiotis, Ritis, Konstantinos, Manfra, Ilenia, Iacobelli, Simona, Huber-Lang, Markus, Nilsson, Bo, Yancopoulou, Despina, Connolly, E. Sander, Garlanda, Cecilia, Ciceri, Fabio, Risitano, Antonio M., Calado, Rodrigo T., Lambris, John D.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier Inc. 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7501834/
https://ncbi.nlm.nih.gov/pubmed/32961333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2020.108598
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky